Xin Xiang Fan

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
BACKGROUND Renal cell carcinoma (RCC) is the most common type of kidney tumor with increasing incidence. Tyrosine Kinase Inhibitors (TKIs) are considered important treatment in the management of metastatic RCC. Some previous studies demonstrated that sorafenib treatment is associated with a significantly increased risk of potentially life-threatening(More)
  • 1